药物开发
药物发现
生化工程
临床前试验
芯片上器官
药品
体内
微流控
风险分析(工程)
计算生物学
医学
生物
药理学
工程类
纳米技术
生物技术
生物信息学
材料科学
作者
Maria Russo,Cesare M. Cejas,Gabriele Pitingolo
出处
期刊:Progress in Molecular Biology and Translational Science
日期:2022-01-01
卷期号:: 163-204
被引量:8
标识
DOI:10.1016/bs.pmbts.2021.07.022
摘要
Drug development is often a very long, costly, and risky process due to the lack of reliability in the preclinical studies. Traditional current preclinical models, mostly based on 2D cell culture and animal testing, are not full representatives of the complex in vivo microenvironments and often fail. In order to reduce the enormous costs, both financial and general well-being, a more predictive preclinical model is needed. In this chapter, we review recent advances in microfluidic 3D cell culture showing how its development has allowed the introduction of in vitro microphysiological systems, laying the foundation for organ-on-a-chip technology. These findings provide the basis for numerous preclinical drug discovery assays, which raise the possibility of using micro-engineered systems as emerging alternatives to traditional models, based on 2D cell culture and animals.
科研通智能强力驱动
Strongly Powered by AbleSci AI